Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accumulated Expenses (2016 - 2025)

IGC Pharma (IGC) has disclosed Accumulated Expenses for 12 consecutive years, with $886000.0 as the latest value for Q3 2025.

  • Quarterly Accumulated Expenses fell 56.44% to $886000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $886000.0 through Sep 2025, down 56.44% year-over-year, with the annual reading at $1.4 million for FY2025, 12.32% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $886000.0 at IGC Pharma, up from $792000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $2.0 million in Q3 2024, with the low at $619000.0 in Q1 2023.
  • Average Accumulated Expenses over 3 years is $1.3 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 153.15% in 2024, then plummeted 56.44% in 2025.
  • Over 3 years, Accumulated Expenses stood at $1.3 million in 2023, then surged by 41.46% to $1.8 million in 2024, then tumbled by 51.37% to $886000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $886000.0, $792000.0, and $1.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.